Post-Transplant Diabetes Management in Renal Recipients

Patients undergoing kidney transplantation face heightened risk of developing diabetes mellitus in the months or years following surgery, a condition known as post-transplant diabetes mellitus (PTDM). This metabolic complication arises from both patient-related factors – such as pre-existing impaired glucose tolerance, obesity and age – and treatment-related influences, notably the diabetogenic effects of immunosuppressive agents. Careful assessment of glucose regulation prior to transplantation, alongside tailored immunosuppressive regimens, is critical to minimise risk. Post-operative monitoring encompasses fasting and post-prandial glucose measurements as well as oral glucose tolerance tests to detect early dysglycaemia. Management strategies combine lifestyle interventions, including structured exercise programmes and dietary modification, with pharmacological therapy ranging from metformin and newer incretin-based agents to individually adjusted insulin regimens in severe cases. Optimisation of immunosuppression – favouring agents with a lower propensity to induce hyperglycaemia – further supports metabolic control. Additionally, close attention to micronutrient status, notably vitamin D and magnesium, has been shown to influence insulin sensitivity. A multidisciplinary approach, integrating transplant physicians, endocrinologists, dietitians and physiotherapists, fosters personalised care. Effective management of PTDM not only improves patient survival and quality of life but also safeguards graft function and reduces the burden of cardiovascular complications that frequently accompany dysregulated glucose metabolism in this population.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Post-Transplant Diabetes Management in Renal Recipients publication trend

The graph below shows the total number of articles in post-transplant diabetes management in renal recipients across all publications each year (not limited to Nature Index journals).

Technical terms

Post-transplant Diabetes Mellitus (PTDM): A form of hyperglycaemia that develops following organ transplantation, influenced by immunosuppressive therapy and patient-related risk factors.

New-Onset Diabetes After Transplantation (NODAT): Diabetes diagnosed post-transplantation in individuals without prior history of diabetes, used interchangeably with PTDM in clinical practice.

Calcineurin Inhibitors: A class of immunosuppressive drugs, including tacrolimus and cyclosporine, that inhibit T-cell activation but carry a risk of inducing hyperglycaemia.

Oral Glucose Tolerance Test (OGTT): A diagnostic procedure measuring blood glucose response to a standardised oral glucose load, used to detect impaired glucose tolerance and diabetes.

Insulin Sensitivity: The efficiency with which cells respond to insulin, a key determinant of glucose uptake and metabolic control, often assessed by indices derived from glucose and insulin measurements.

References

1. Posttransplant complications: molecular mechanisms and therapeutic interventions. MedComm (2024).
2. Exercise and Prediabetes After Renal Transplantation (EXPRED-I): A Prospective Study. Sports Medicine - Open (2023).
3. New-Onset Diabetes after Kidney Transplantation. Medicina (2021).